Sorsby Fundus Dystrophy (SFD) is a rare, inherited genetic eye disorder that primarily affects the macula, the central part of the retina responsible for sharp, detailed vision. First described by Arnold Sorsby in 1949, this condition is characterized by progressive vision loss that often mimics the symptoms of age-related macular degeneration (AMD). However, unlike AMD, which typically affects older adults, SFD usually presents much earlier, often between the third and sixth decades of life.
The condition is caused by mutations in the TIMP3 gene, which provides instructions for making a protein that helps maintain the structural integrity of the retina. When this gene is mutated, it leads to the abnormal buildup of deposits under the retina, disrupting its normal function. Over time, this can cause the growth of abnormal, leaky blood vessels beneath the macula—a complication known as choroidal neovascularization (CNV).
One of the earliest symptoms of Sorsby Fundus Dystrophy is night blindness, where individuals struggle to see in low-light conditions. Some patients also report difficulty distinguishing between certain colors, such as blue from green or yellow from red. As the disease progresses, individuals may experience a gradual decline in central vision, making tasks like reading, driving, and recognizing faces increasingly difficult. Peripheral (side) vision is usually preserved until the later stages of the disease.
Diagnosing SFD typically involves a comprehensive eye examination, including imaging tests like optical coherence tomography (OCT) and fluorescein angiography, which can reveal the characteristic changes in the retina and the presence of abnormal blood vessels. Genetic testing is also crucial to confirm the diagnosis by identifying the specific mutation in the TIMP3 gene.
While a diagnosis of Sorsby Fundus Dystrophy can be daunting, understanding the condition is the first step in managing it effectively. Regular monitoring by an ophthalmologist or a retina specialist is essential to detect and treat complications like CNV early, which can help preserve vision for as long as possible. Patients are strongly encouraged to consult their healthcare provider for personalized advice and management strategies tailored to their specific needs.